🔎 Trials Near Me

Hjem › Autoimmune sykdommer › Illinois

Kliniske studier for Autoimmune sykdommer i Illinois

14 studier for Autoimmune sykdommer søker deltakere på steder i Illinois.

Byer i Illinois

Offisiell studietekst (engelsk)

Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden

  • Willow Rheumatology Wellness, Willowbrook
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07621809

A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis

  • University of Chicago, Chicago
RekruttererFase 2
Alder 16 til 70 · Alle kjønn · Oppdatert 17. sep. 2026 · NCT07328581

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

  • Ann & Robert H. Lurie Children's Hospital of Chicago - Accepting Young Adult and Juvenile Patients, Chicago
  • Northwestern Memorial Hospital - Accepting Adult Patients, Chicago
  • The University of Chicago Medical Center - Accepting Adult and Juvenile Patients, Chicago
RekruttererFase 2/3
Alder 6 til 75 · Alle kjønn · Oppdatert 17. sep. 2026 · NCT06154252

Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy

  • University of Chicago, Department of Medicine: Rheumatology, Chicago
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 17. sep. 2026 · NCT07103746

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

  • The University of Chicago Medical Center, Chicago
RekruttererFase 1
Alder 18 til 74 · Alle kjønn · Oppdatert 10. sep. 2026 · NCT07085104

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

  • Northwestern Memorial Hospital, Chicago
  • The University of Chicago Medical Center, Chicago
RekruttererFase 1/2
Alder 18 til 65 · Alle kjønn · Oppdatert 26. aug. 2026 · NCT06121297

A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus

  • University of Illinois Hospital & Health Sciences System, Chicago
RekruttererFase 1/2
Alder 35 til 70 · Alle kjønn · Oppdatert 21. aug. 2026 · NCT06575426

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

  • Northwestern Memorial Hospital, Chicago
  • The University of Chicago Medical Center, Chicago
RekruttererFase 2/3
Alder 18 til 75 · Alle kjønn · Oppdatert 17. aug. 2026 · NCT06328777

RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

  • Northwestern Memorial Hospital, Chicago
RekruttererFase 1/2
Alder 18 til 70 · Alle kjønn · Oppdatert 13. aug. 2026 · NCT06359041

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

  • Site Number - 1054, Schaumburg
RekruttererFase 3
Alder 18 til 80 · Alle kjønn · Oppdatert 30. jul. 2026 · NCT07039916

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • Northwestern Memorial Hospital, Chicago
  • Rush University Medical Center, Chicago
  • University of Illinois at Chicago, Chicago
  • og 3 flere
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 6. jul. 2026 · NCT01351545

Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis

  • Northwestern University, Chicago
RekruttererFase 1
Alder 18 til 70 · Alle kjønn · Oppdatert 30. jun. 2026 · NCT06201416

The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing

  • University of Chicago Medical Center, Chicago
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 18 og eldre · Alle kjønn · Oppdatert 4. mar. 2026 · NCT01280825

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.